Effects of Chemotherapy on Muscle Mass and Exercise Performance in Patients With Oesophageal Cancer.

Effect of Neoadjuvant Chemotherapy on Muscle Mass and Peri-operative Cardiorespiratory Performance in Patients Undergoing Oesophageal Cancer- a Pilot Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01742312

Acronym

Oeso-Chemo

Enrollment

Registered

2012-12-05

Start date

2011-10-31

Completion date

2013-01-31

Last updated

2016-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oesophageal Adenocarcinoma

Keywords

neoadjuvant chemotherapy, oesophageal cancer, cardiorespiratory performance

Brief summary

Curative treatment for oesophageal cancer involves undertaking chemotherapy followed by an operation to remove the tumour. Chemotherapy has several effects upon the body, including effects upon the systems that control the creation and breakdown of muscle. We aim to review these effects by recording changes in the amount of exercise patients are able to undertake after chemotherapy and reviewing changes in muscle mass.

Detailed description

We aim to review the effects of chemotherapy on skeletal muscle mass and cardio-respiratory performance in patients with oesophageal adenocarcinoma. All patients will be assessed by a Consultant Anaesthetist and a medical member of the Research team before commencing chemotherapy and after finishing their course. These assessments include a nutritional assessment, performance status assessments, blood assays, dual energy X-ray absorptiometry (DEXA) scans, cardio-pulmonary exercise (CPEX) testing and a muscle biopsy.

Interventions

RADIATIONDEXA scan

all patients will undertake a full body DEXA scan before and after chemotherapy

PROCEDUREMuscle biopsy

All patients will have a muscle biopsy before and after chemotherapy

OTHERcardio-pulmonary exercise testing (CPEX)

patients will undertake exercise in the form of an exercise bike whilst having their cardiac and ventilatory performance analysed. This will take place before and after neoadjuvant chemotherapy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* oesophageal cancer * Multidisciplinary team decision to offer neoadjuvant chemotherapy prior to surgery

Exclusion criteria

* Metastatic disease

Design outcomes

Primary

Measure	Time frame	Description
muscle mass	3 months	variations in muscle mass during neoadjuvant chemotherapy

Secondary

Measure	Time frame	Description
nutritional status	3 months	assess nutritional status post chemotherapy via serum protein levels.
all cause mortality	3 months	Evidence of mortality and relate this to aerobic ability.
mitochondrial function performance status	3 months	review changes in mitochondrial function after neoadjuvant chemotherapy
cardiorespiratory performance (peak VO2)	3 months	review changes in cardiorespiratory performance (peak VO2) after neoadjuvant chemotherapy

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026